Regulatory affairs consulting for biotech: what support do you need?
A guide for biotech founders, development leaders and regulatory leads assessing external support: which regulatory services exist, when to bring them in, what a regulatory development plan should contain and what to ask a provider.
By VCLS (Voisin Consulting Life Sciences)
Reviewed by Anthony Murray, Head of Marketing & Communications, VCLS, 22 October 2026.
Regulatory affairs consulting helps biotech companies plan the evidence, agency interactions and submissions needed to develop and maintain a medicinal product. Support can include regulatory strategy, application preparation, responses to regulators and post-approval change management. The appropriate scope depends on the product, its development stage, the intended markets and the next decision.
For a biotech company, a useful starting point is to identify the decision the business needs to make: whether a program is ready for clinical development, how to prepare for regulatory advice, what is needed for an application, or how a proposed change affects an approved product.
This guide focuses on medicines, including biologics, with examples from the United States and European Union.
What services does regulatory affairs consulting cover?
Three connected areas of support address different needs.
Three areas of regulatory support
| Service | The question it helps answer | Examples of work to agree in the scope |
|---|---|---|
| Regulatory strategy | What development and regulatory approach fits this product and its intended use? | Pathway assessment, evidence-gap analysis, development roadmap and agency interaction planning |
| Regulatory operations and submissions | How will we turn the evidence into a complete, consistent application and manage the submission process? | Dossier authoring and review, document coordination, electronic publishing, submission management and responses to authority questions |
| Regulatory lifecycle management | What regulatory work is needed as the product, manufacturing process or approved use changes? | Change assessment, application maintenance, variations or supplements, and planning for additional indications or markets |
These activities need to inform one another. A strategy may identify an evidence gap that affects the submission date. A manufacturing change may require an assessment of its impact on the development program or an existing authorization.
Figure 1
Where each area of regulatory support is usually active
- Regulatory strategy: from candidate selection to the marketing application, and again whenever a change or a new market reopens the development questions.
- Operations and submissions: from the first clinical trial application through agency briefing packages to the marketing application, then for variations and supplements after approval.
- Lifecycle management: from approval onward, covering changes to the product, process or approved use, additional indications and new markets.
VCLS provides strategic regulatory planning, regulatory operations and submissions, and lifecycle management. The precise deliverables should be defined for each engagement.
When should a biotech company bring in regulatory support?
Consider regulatory input before a decision commits the company to significant studies, manufacturing work or a filing timetable. The aim is to understand what the next milestone requires while there is still time to address gaps.
When to bring in regulatory support
| Your next decision | Useful regulatory work | A practical output to request |
|---|---|---|
| Select a development approach for an early asset | Assess the intended use, relevant pathways and available evidence | A roadmap showing assumptions, gaps and decision points |
| Prepare for a first clinical trial | Review how manufacturing, nonclinical and clinical information fit the proposed trial | A readiness assessment with actions, owners and dependencies |
| Seek advice on a development plan | Identify the questions that could change the program and prepare the supporting rationale | A focused question list, briefing package and plan for applying the feedback |
| Prepare a clinical trial or marketing application | Assess content readiness and coordinate authors, reviewers and publishing | A submission plan identifying required documents, responsibilities and unresolved issues |
| Add a new market | Compare existing evidence and regulatory history with the intended market’s needs | A market-specific gap assessment and submission sequence |
| Change an approved product or its manufacturing | Assess the regulatory consequences and applicable procedures | A change and submission plan coordinated with quality and supply teams |
Examples of useful project outputs, not a universal list of documents required by regulators.
These are examples of useful project outputs, rather than a universal list of documents required by regulators.
Regulatory support can also be targeted. A company with an experienced internal regulatory lead may need specialist input on a modality, an additional jurisdiction or a particular submission. Another company may need a team to coordinate several disciplines over a longer period.
What should a regulatory development plan include?
A useful regulatory plan connects the intended product and patient population to the evidence needed at each development milestone.
It should bring together chemistry, manufacturing and controls (CMC), nonclinical and clinical work. For example, FDA describes an investigational new drug application (IND) as covering nonclinical pharmacology and toxicology, manufacturing information, and clinical protocols and investigator information. Preparing for an IND therefore requires coordination across these areas.1
When agreeing a regulatory strategy project, ask for:
- The proposed pathway and the reasons for selecting it.
- The evidence available, the important gaps and the assumptions that still need testing.
- Decisions that would benefit from authority input.
- The sequence of studies, manufacturing activities and submissions, including dependencies.
- Clear ownership of the next actions and a process for updating the plan.
A plan should be revisited when new data, agency feedback, manufacturing changes or business decisions alter its assumptions.
Can one development program support both US and EU plans?
A coordinated program can consider US and EU objectives together, but the company still needs to assess the evidence and procedures relevant to each jurisdiction. Alignment should be evaluated for the product and proposed use.
For clinical development, the US IND and EU clinical trial application are distinct regulatory processes. In the EU, applications under the Clinical Trials Regulation are submitted through the Clinical Trials Information System (CTIS). EU Member States and European Economic Area countries are responsible for trial evaluation, authorization and supervision.1, 2
EMA scientific advice is a separate service that can inform development methods and study design. It is not an EU clinical trial authorization. EMA also states that its scientific advice is not legally binding in relation to a future marketing authorization application.3
For a company targeting both markets, useful consulting work includes identifying where the evidence plan can be shared, where additional work may be needed, and which questions should be raised with the relevant authorities.
How can consultants support meetings and scientific advice?
Consultants can help the company define the purpose of an interaction, select questions, explain the proposed approach and prepare supporting documents.
The work should begin with the development decision. For example, does the team need feedback on a proposed clinical endpoint, a nonclinical study design or a manufacturing development approach? The briefing material should explain the proposal and why the company considers it appropriate.
After the interaction, the team should document the feedback, its implications and any actions needed. EMA describes scientific advice as prospective guidance on a developer’s proposals; it does not pre-evaluate study results or guarantee marketing authorization.3
A useful deliverable is therefore a documented interpretation of the feedback and an updated development plan.
What should you ask a regulatory consulting provider?
Evaluate the proposed team and scope against the work your product needs.
- Relevant experience: Has the team worked with the product type, development stage and intended jurisdictions?
- Access to the right disciplines: Who will address CMC, nonclinical and clinical questions when these affect the regulatory approach?
- Specific deliverables: Will the engagement produce advice, a written assessment, a development plan, authored documents, submission support, or a combination?
- Execution responsibilities: Who will coordinate contributors, review the work, manage authority correspondence and resolve outstanding questions?
- Continuity: How will decisions, assumptions and regulatory history be recorded and handed over?
These questions also help when comparing support from a consultancy, a contract research organization (CRO) or several specialist providers. Check the actual scope and responsibilities: the provider’s label alone does not establish what is included.
What information should you prepare for an initial discussion?
A short brief can make the discussion more productive. Include the product and proposed indication, development stage, available evidence, intended markets, previous regulatory interactions and the next decision or milestone.
Explain who is already involved internally and externally, which activities are covered, and where additional support is needed.
Frequently asked questions
What is included in regulatory submission support?
Regulatory submission support turns the evidence a company holds into a complete, consistent application and manages the process around it. It usually covers dossier authoring and review, coordination of the contributing documents, electronic publishing, submission management and responses to questions from the authority. It is distinct from regulatory strategy, which decides what the application needs to contain, and the two should be scoped together so that a gap found during authoring is not discovered at the filing date.
What regulatory support is needed after a medicine is approved?
After approval, regulatory work follows the product. A change to the manufacturing process, the approved use, the labeling or the supply arrangements needs an assessment of its regulatory consequences and the applicable procedure, which in the EU is a variation and in the US a supplement. Lifecycle management also covers application maintenance, planning for additional indications and markets, and keeping the regulatory history in a form the next team can use. It is coordinated with quality and supply, because those teams usually trigger the change.
Is a regulatory consultancy different from a contract research organization (CRO)?
Both can provide regulatory services, and the label alone does not establish what is included. A consultancy, a CRO and a set of specialist providers can each cover strategy, submissions or lifecycle work, with different depth in each. The questions above apply whichever type of provider is being considered: who is on the team, which disciplines they can bring in, what the deliverables are, who carries execution responsibility and how the regulatory history will be recorded and handed over.
Terms used in this guide
- Regulatory pathway
- The route by which a product is developed and assessed for approval, chosen for the product type and its intended use. The pathway determines what evidence is needed and which procedures apply.
- IND
- Investigational new drug application: the US submission that allows an investigational medicine to be given to people in clinical trials. FDA describes it as covering nonclinical pharmacology and toxicology, manufacturing information, and clinical protocols and investigator information.
- Clinical trial application
- The EU process for authorizing a clinical trial, submitted under the Clinical Trials Regulation through the Clinical Trials Information System (CTIS). Member States evaluate, authorize and supervise trials.
- Scientific advice
- An EMA service in which developers ask questions about their proposed development approach. The advice is prospective, is not a trial authorization and is not legally binding on a future marketing authorization application.
- CMC
- Chemistry, manufacturing and controls: the information describing how a product is made and tested. CMC decisions affect the evidence a submission needs and are a frequent source of late changes.
- Gap assessment
- A review of the evidence and documentation a company holds against what a specific milestone or submission requires, producing a list of gaps, assumptions to test and actions with owners.
- Variation / supplement
- The regulatory procedures for changing an approved product: a variation in the EU and a supplement in the US. The category of change determines the procedure and whether approval is needed before implementation.
How can VCLS support your regulatory program?
VCLS (Voisin Consulting Life Sciences) supports regulatory strategy, submissions and lifecycle management, drawing on regulatory, CMC, nonclinical and clinical expertise.
The starting point is your product and the decision you need to make. From there, the scope can be defined around the relevant development questions, agency interactions and submission activities.
